SUPERNUS PHARMACEUTICALS, INC.

NASDAQ: SUPN (Supernus, Inc.)

Kemas kini terakhir: 13 Nov, 6:43AM

29.20

-0.25 (-0.85%)

Penutupan Terdahulu 29.45
Jumlah Dagangan 4,365,750
Purata Dagangan (3B) 2,762,359
Modal Pasaran 5,942,986,752
Harga / Jualan (P/S) 1.94
Harga / Buku (P/B) 1.59
Julat 52 Minggu
25.92 (-11%) — 42.81 (46%)
Tarikh Pendapatan 29 Oct 2026
Hasil Dividen (DY TTM) 27.84%
Margin Keuntungan 32.75%
Margin Operasi (TTM) 46.94%
EPS Cair (TTM) -0.760
Pertumbuhan Hasil Suku Tahunan (YOY) 13.40%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 226.20%
Jumlah Hutang/Ekuiti (D/E MRQ) 3.13%
Nisbah Semasa (MRQ) 0.620
Aliran Tunai Operasi (OCF TTM) 96.00 M
Aliran Tunai Bebas Leveraj (LFCF TTM) 227.12 M
Pulangan Atas Aset (ROA TTM) 29.34%
Pulangan Atas Ekuiti (ROE TTM) 6.32%

AISkor Stockmoo

-1.0
Hutang rendah. Keuntungan kukuh. Kecairan jangka pendek nipis. Aliran tunai positif. info
Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info NA
Penilaian Relatif info NA
Pertumbuhan Tersirat info NA
Sejarah Penilaian info NA
Pulangan atas Modal info NA
Trend Perolehan info NA
Nilai Pegangan info NA
Premium Risiko info NA
Penilaian Pasaran info NA
Tiada aliran jelas sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info
Aliran menurun: harga di bawah purata bergeraknya, dan purata itu sedang menurun. Harga hampir dengan purata itu. info
Daripada analisis teknikal AI kami terhadap carta. info NA
Corak Lilin info NA
Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info
Berita terkini kebanyakannya positif. info
Sentimen Pegangan info NA
Aktiviti Orang Dalam info NA
Aliran Institusi info NA
Kedudukan Jual Singkat info NA
Persekitaran pasaran berhati-hati. info
Sektor mengatasi prestasi pasaran.
Tonggak-tonggak sependapat, jadi skor diperkukuh.
Di bawah garis aliran jangka sederhana. info
Harga rendah berbanding purata 52 minggunya. Naik dalam tempoh 5 tahun. info
Aliran turun bagi ketiga-tiga tempoh. Momentum jangka pendek menurun. info
Harga hampir dengan paras rintangan. info
Skor Akhir -0.96
Tunjuk semua

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - Specialty & Generic (US) Bercampur Bercampur
Drug Manufacturers - Specialty & Generic (Global) Bercampur Bercampur
Stok Supernus, Inc. Bercampur Menaik

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B Skor
SUPN 6 B 27.84% - 1.59 -1.0
ANIP 2 B - 13.74 2.57 -0.1
COLL 783 M - 23.13 2.72 0.1
TKNO 480 M - - - 0.8
AQST 435 M - - - -1.7
TLRY 279 M - - 0.200 -2.2

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Sektor Healthcare
Industri Drug Manufacturers - Specialty & Generic
Gaya Pelaburan Small Value
% Dimiliki oleh Orang Dalam 2.06%
% Dimiliki oleh Institusi 61.81%

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

5 Positif 0 Negatif 4 Neutral
Tarikh Jenis Butiran
10 Nov 2026 Yahoo Finance Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London
ROCKVILLE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus, Inc., will…
10 Nov 2026 Yahoo Finance Supernus (SUPN) Stock Still Looks Undervalued As Its 127% 5 Year Run Continues
Supernus has had a volatile few years, and with the share price at US$27.62 after a sharp pullback, the key issue is whether that price still lines up with what its earnings can reasonably support. Over the past 5 years, Supernus has delivered a 127.5% share price gain. This puts real weight on the…
09 Nov 2026 Yahoo Finance Supernus undervalued after Indivior merger, says Bank of America
Bank of America has initiated coverage of Supernus Pharmaceuticals (NASDAQ:SUPN) with a 'buy' rating and a $47 price target, arguing that its merger with Indivior creates a larger business with stronger earnings potential. The combined group has a broader portfolio of treatments for nervous…
04 Nov 2026 Yahoo Finance Supernus Pharmaceuticals (SUPN) After Its Indivior Merger Looks Undervalued
Supernus Pharmaceuticals (SUPN) just completed its all‑stock merger with Indivior Pharmaceuticals, creating Supernus, Inc., and simultaneously requested delisting of its legacy shares after multiple index removals connected to the transaction. Recent trading tells a mixed story for Supernus…
03 Nov 2026 Yahoo Finance Supernus Pharmaceuticals (SUPN) Stock May Be Undervalued After ONAPGO Exclusivity
Supernus Pharmaceuticals has had a mixed share price journey, with the stock up strongly over three years but weaker over the past year. That puts fresh attention on what investors are paying for its current level of sales. With new products, a merger closing and a changing revenue mix all in play…
03 Nov 2026 Yahoo Finance What Changes For Supernus Pharmaceuticals (SUPN) After Its Nasdaq Delisting And Merger?
Supernus Pharmaceuticals (NasdaqGM:SUPN) has completed its merger of equals with Indivior Pharmaceuticals, forming a combined specialty pharma business. As part of the transaction, Supernus shares have been delisted from Nasdaq, with equity now rolling into the new merged entity. The deal includes…
02 Nov 2026 Yahoo Finance Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader
Merger positions Supernus as a leading diversified central nervous system (CNS) biopharmaceutical company with a broad portfolio of marketed medicines, enhanced financial flexibility and a differentiated pipelineSignificantly enhances cash flow profile and scale, unlocking greater capacity to…
02 Nov 2026 Yahoo Finance Why Indivior Pharmaceuticals Stock Topped the Market Today
The company is merging with a peer.
31 Oct 2026 Yahoo Finance SUPN Q3 deep dive: robust portfolio growth and integration priorities amid Indivior merger
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) announced better-than-expected revenue in Q3 2026, with sales up 18.1% year on year to $226.8 million. The company’s full-year revenue guidance of $887.5 million at the midpoint came in 1.5% above analysts’ estimates. Its…
30 Oct 2026 Yahoo Finance Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Turnaround Narrative
Indivior Pharmaceuticals (INDV) moved back into focus after reporting record third quarter earnings and reaffirming its 2026 revenue outlook. This gave investors fresh numbers to weigh alongside an approved merger with Supernus Pharmaceuticals. Over the past year Indivior Pharmaceuticals has…
30 Oct 2026 Yahoo Finance Supernus Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
Moby summary of Supernus Pharmaceuticals, Inc.'s Q3 2026 earnings call…
30 Oct 2026 Yahoo Finance Supernus (SUPN) Q3 2026 Earnings Call Transcript
Qelbree prescriptions surged 18% as revenue hit $226.8 million ahead of Indivior merger.
30 Oct 2026 Yahoo Finance Indivior Pharmaceuticals (INDV) Shareholders Back Merger After Record Third Quarter
Indivior Pharmaceuticals (NasdaqGS: INDV) reported record third quarter results, highlighting its strongest Q3 performance to date. Shareholders approved a merger with Supernus Pharmaceuticals that will see the combined business operate under the Supernus brand. The transaction is expected to close…
29 Oct 2026 Yahoo Finance Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of +89.80% and +1.39%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
29 Oct 2026 Yahoo Finance Supernus Pharmaceuticals Q3 Earnings Call Highlights
Supernus Pharmaceuticals (NASDAQ:SUPN) reported record third-quarter revenue and higher sales across its growth portfolio, while management said its planned merger with Indivior Pharmaceuticals is expected to close Nov. 2 following shareholder approvals. Total revenue rose 18% year over year to $22…
29 Oct 2026 Yahoo Finance Supernus: Q3 Earnings Snapshot
(AP) — Supernus Pharmaceuticals Inc. (SUPN) on Thursday reported profit of $20…
29 Oct 2026 Yahoo Finance Supernus Pharmaceuticals (NASDAQ:SUPN) delivers impressive Q3 2026, full-year sales guidance is optimistic
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) beat Wall Street’s revenue expectations in Q3 2026, with revenue rising 18.1% year on year to $226.8 million. The company’s full-year revenue guidance of $887.5 million at the midpoint came in 1.5% above analysts’ consensus…
29 Oct 2026 Yahoo Finance Supernus Announces Third Quarter 2026 Financial Results
Record total revenues of $226.8 million in the third quarter 2026, an 18% increase compared to same period last year.Combined revenues of the Company's four growth products increased to $192.2 million in the third quarter 2026, representing an increase of 29% compared to the same period last year.…
Papar semua
Hasil Dividen (DY TTM) 27.84%
Jangkaan Pembayaran Dividen Seterusnya Nov 2027
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
03 Nov 2026 16 Sep 2026 06 Nov 2026 8.13 Tunai

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2026 8.13 1 27.84

Isyarat Terkini corak lilin dan silang EMA

▼ Silang maut 8 sesi lalu · 10 Nov
Jangka panjang · EMA 50/200
EMA 50 hari melintas ke bawah EMA 200 hari, tanda yang diperhatikan ramai bahawa arah aliran jangka panjang telah berubah menurun.

Persediaan Teknikal Sederhana

Susunan aliran
Kecerunan
Kemasukan
Dagangan
Aliran menurun: harga di bawah purata bergeraknya, dan purata itu sedang menurun. Harga hampir dengan purata itu.
Sokongan terdekat: 27.30 – 29.04 · paras kukuh
Rintangan terdekat: 29.02 – 31.17 · paras kukuh

AI Analisis Teknikal

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Risiko / Ganjaran
TP1:
TP2:

Kerugian hingga SL berbanding keuntungan hingga setiap sasaran, dari EP. Nisbah 2 atau lebih biasanya dicari.

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda